ADVANCED UROTHELIAL CARCINOMA AND IMPAIRED RENAL FUNCTION

Anticancer Drugs. 2011 Sep 20. [Epub ahead of print]

Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.

Demery ME, Thézenas S, Pouessel D, Culine S.

Source

aDepartment of Medical Oncology, University Hospital, Nîmes bDepartment of Biostatistics, Val d'Aurelle Cancer Center, Montpellier cDepartment of Medical Oncology, Saint-Louis University Hospital, Paris, France.

Abstract

Cisplatin is the backbone of chemotherapeutic regimens used in the treatment of advanced transitional cell carcinoma of the urothelium. However, about 50% of patients cannot be administered cisplatin because of impaired renal functions. A review of the different approaches that have been developed in this patient population was performed through a Medline search from 1 January 1998 to 31 December 2010. Twenty-six studies including 25 phase II and one randomized phase II/III studies were analyzed. All regimens, except one, were based on gemcitabine and/or carboplatin and/or paclitaxel. Only five (20%) out of 25 phase II studies actually include homogeneous patients with an impaired renal function defined by a creatinine clearance below 60 ml/min. One hundred and eight patients with a median creatinine clearance ranging from 28 to 48 ml/min received four different chemotherapy regimens including one to four drugs. The results showed the response rates to vary from 24 to 56% and survival to range from 7 to 15 months. No standard chemotherapy can be recommended from literature data. Future randomized studies will have to solve the following questions: what is the optimal definition of cisplatin eligibility? Which platinum salt should be used? Is a platinum salt necessary? How many drugs should be delivered?